• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Cedar Pollen Allergy - Pipeline Review, H2 2012 Product Image

Cedar Pollen Allergy - Pipeline Review, H2 2012

  • ID: 2366439
  • December 2012
  • 40 pages
  • Global Markets Direct

Cedar Pollen Allergy – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Cedar Pollen Allergy - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Cedar Pollen Allergy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cedar Pollen Allergy. Cedar Pollen Allergy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Cedar Pollen Allergy.
- A review of the Cedar Pollen Allergy products under development by companies and universities/research READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Cedar Pollen Allergy Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Cedar Pollen Allergy 7
Cedar Pollen Allergy Therapeutics under Development by Companies 9
Late Stage Products 10
Comparative Analysis 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Discovery and Pre-Clinical Stage Products 13
Comparative Analysis 13
Cedar Pollen Allergy Therapeutics – Products under Development by Companies 14
Companies Involved in Cedar Pollen Allergy Therapeutics Development 15
Taiho Pharmaceutical Co., Ltd. 15
Allergy Therapeutics plc 16
Torii Pharmaceutical Co., Ltd. 17
ANERGIS SA 18
REGiMMUNE Corporation 19
Immunomic Therapeutics, Inc. 20
Biomay AG 21
Cedar Pollen Allergy – Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
Pollinex Quattro Japanese Cedar - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
RGI-1001 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Japanese Cedar Hypoallergenic Vaccine - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
TAC-201 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
TO-194SL - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
JRC-LAMP-vax - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Product Description 33
Mechanism of Action 33
R&D Progress 33
Cedar Pollen Vaccine - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Cedar Pollen Allergy Therapeutics – Drug Profile Updates 35
Cedar Pollen Allergy Therapeutics - Dormant Products 36
Cedar Pollen Allergy – Product Development Milestones 37
Featured News & Press Releases 37
Nov 08, 2012: Immunomic Therapeutics Doses First Patient In Phase I Clinical Trial Of JRC-LAMP-Vax Vaccine To Treat Japanese Red Cedar Allergy 37
Sep 14, 2012: Torii Pharma Announces Top-line Results Of Phase III Clinical Study Of TO-194SL 38
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 40
Disclaimer 40

List of Tables
Number of Products Under Development for Cedar Pollen Allergy, H2 2012 7
Products under Development for Cedar Pollen Allergy – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Comparative Analysis by Late Stage Development, H2 2012 10
Comparative Analysis by Mid Clinical Stage Development, H2 2012 11
Comparative Analysis by Early Clinical Stage Development, H2 2012 12
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Taiho Pharmaceutical Co., Ltd., H2 2012 15
Allergy Therapeutics plc, H2 2012 16
Torii Pharmaceutical Co., Ltd., H2 2012 17
ANERGIS SA, H2 2012 18
REGiMMUNE Corporation, H2 2012 19
Immunomic Therapeutics, Inc., H2 2012 20
Biomay AG, H2 2012 21
Assessment by Monotherapy Products, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 26
Cedar Pollen Allergy Therapeutics – Drug Profile Updates 35
Cedar Pollen Allergy Therapeutics – Dormant Products 36

List of Figures
Number of Products under Development for Cedar Pollen Allergy, H2 2012 7
Products under Development for Cedar Pollen Allergy – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Late Stage Products, H2 2012 10
Mid Clinical Stage Products, H2 2012 11
Early Clinical Stage Products, H2 2012 12
Discovery and Pre-Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 22
Assessment by Route of Administration, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Molecule Type, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 26

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos